Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2018-11-13 Interim / Quarterly Rep…
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release of third quarter financial results and condensed consolidated interim unaudited financial information for the three and nine months ended September 30, 2018. Form 6-K filings typically provide interim or quarterly updates for foreign issuers and are not full annual reports. The presence of interim unaudited financial information aligns with an Interim / Quarterly Report. The document length is 2246 characters, which is consistent with a report rather than a brief announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2018-11-13 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about hosting a third quarter 2018 financial results conference call. The document is short (1960 characters) and primarily serves as an announcement of the upcoming earnings call rather than containing detailed financial data or the call transcript itself. Form 6-K filings are typically used for current reports by foreign private issuers and often include press releases or other announcements. Since this document does not contain the actual earnings release or transcript but announces the event, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than an Earnings Release (ER) or Call Transcript (CT).
2018-11-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about an upcoming analyst and investor webcast. The document is short (1958 characters) and does not contain financial statements or detailed financial data. It is primarily an announcement of an event (webcast) rather than a full report or detailed financial disclosure. Form 6-K filings typically serve as periodic reports for foreign issuers and often include press releases or other material information. Given the nature and length of the document, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-10-29 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a presentation at a conference (BIO-Europe 2018). The document is short (1922 characters) and primarily serves as a regulatory filing to report this event. It does not contain financial statements, detailed financial data, or comprehensive reports. According to the rules, Form 6-K filings are considered Regulatory Filings (RNS) as they are periodic reports submitted by foreign private issuers to disclose material information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-10-25 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about a clinical study milestone but does not contain detailed financial statements or comprehensive financial analysis. The document length is short (1983 characters), and it primarily serves as a regulatory announcement of a press release rather than a full report. According to the rules, Form 6-K filings with press releases or announcements are classified as Regulatory Filings (RNS) because they do not constitute full financial reports or detailed presentations.
2018-10-24 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about additional data from a Phase III study, which is typical content for a Form 6-K. The document length is only 2015 characters, indicating it is a short report or announcement rather than a full financial report. Form 6-K filings are periodic reports for foreign private issuers to disclose material information and are classified under Regulatory Filings (RNS) as they do not fit into other specific categories like Annual Report or Interim Report. There is no detailed financial data or comprehensive report content here, just a press release attached and incorporated by reference.
2018-10-22 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.